Table 1.
Study population characteristics (n = 36)
| Median [range] age (yr) | 55 [37-87] |
|---|---|
| Histotype# | |
| Invasive ductal carcinoma | 28 (77.7%) |
| Invasive lobular carcinoma | 5 (13.8%) |
| Mixed (ductal and lobular) | 2 (5.5%) |
| Undifferentiated | 1 (3.0%) |
| Grading° | |
| G2 | 21 (58.3%) |
| G3 | 15 (41.7%) |
| ER status | |
| Negative | 14 (38.8%) |
| Positive | 22 (61.2%) |
| PgR status | |
| Negative | 13 (36.1%) |
| Positive | 23 (63.9%) |
| HER2 status* | |
| Negative | 27 (75.0%) |
| Positive | 9 (25.0%) |
| Adjuvant chemotherapy^ | |
| FEC | 18 (52.9%) |
| EC | 11 (32.4%) |
| CMF | 5 (14.7%) |
| Mean ± SD time to first relapse (months) | 15.8 ± 6.5 |
| Metastatis sites | |
| Bone | 21 (58.3%) |
| Liver | 21 (58.3%) |
| Lung | 16 (44.4%) |
| Lymphnodes | 14 (38.8%) |
| Local | 3 (8.3%) |
| Chemotherapy" | |
| TXT75 | 14 (38.8%) |
| TXT25 | 8 (22.2%) |
| TXT75+C | 5 (13.8%) |
| TXT75+T | 9 (25.2%) |
| Treatment best response | |
| Complete response | 1 (2.7%) |
| Partial response | 14 (38.8%) |
| Stable disease | 12 (33.3%) |
| Disease progression | 9 (25.2%) |
| Time to disease progression (months) | |
| Median [range] | 9 [2-54] |
| Overall survival (months) | |
| Median [range] | 20 [3-101] |
#According to WHO hystological typing of breast tumor (Ref. 32). °According to Elston and Ellis classification (Ref. 31). *Pre-study determination. "See text for regimen details. ^on 34 pts.